Weisea JB et al. – LOXL4 is a useful as a tumor marker and target in the treatment of head and neck squamous cell carcinomas (HNSCC) Methods
Study of the diagnostic and prognostic value of LOXL4 expression in 317 human HNSCC specimens
Results
LOXL4 protein found in 92.7% of primary tumors, in 97.8% of lymph node metastases, and in affected oral mucosa with high-grade dysplasia; absent in non-neoplastic head and neck tissues
TNM categories and overall survival did not link to immunoreactivity grades
Cultured primary hypopharyngeal HTB-43 carcinoma cells showed perinuclear and cell surface expression of LOXL4, but no nuclear localization
See all
